title: Boron neutron capture in prostate cancer cells.
abstract: A modified enhanced thermal neutron beam (METNB) assembly at Fermilab was used to irradiate borylphenylalanine (BPA) treated human prostate cancer cells, DU 145. Acceptable cellular uptake levels of BPA and no BPA cytotoxicity were observed. In the absence of BPA, the relative biological effectiveness (RBE) of the METNB was determined to be 2.3-4.8 times greater than gamma rays. An additional 1.2 or 1.4 fold relative enhancement from boron neutron capture (RE(BNC)) was observed for METNB irradiated DU 145 cells treated with 4.9 or 12mM BPA, respectively. The additional cell killing of the BPA loaded DU 145 cells by the METNB at Fermilab is evidence for a BNC enhanced cell killing.
authors.affiliation: Department of Biological Sciences, Northern Illinois University, DeKalb, IL 60115-2862, USA. lyasui@niu.edu
authors.forename: Linda
authors.initials: L
authors.lastname: Yasui
authors.forename: Thomas
authors.initials: T
authors.lastname: Kroc
authors.forename: Samantha
authors.initials: S
authors.lastname: Gladden
authors.forename: Christine
authors.initials: C
authors.lastname: Andorf
authors.forename: Sajit
authors.initials: S
authors.lastname: Bux
authors.forename: Narayan
authors.initials: N
authors.lastname: Hosmane
mesh_terms: D016754:Boron Neutron Capture Therapy / Q000379:methods*; D045744:Cell Line, Tumor; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D016896:Treatment Outcome